AffiliationDepartment of Acute Medicine and Critical Care, The Christie, Manchester, UK.
MetadataShow full item record
AbstractPurpose of review: Emergency presentations in patients treated with immune checkpoint inhibitors (ICIs) are a clinical challenge. Clinicians need to be vigilant in diagnosing and treating immune-mediated toxicities. In this review, we consider the approach to managing an acutely unwell patient being treated with ICIs presenting as an emergency. Recent findings: A minority of acutely unwell patients treated with ICIs will have an immune-mediated toxicity. Early recognition and intervention in those with immune-mediated toxicity can reduce the duration and severity of the complications. The use of early immunosuppressive agents along corticosteroid therapy may improve outcomes in patients with life-threatening immune-mediated toxicity. Summary: Individualized management of immune-mediated toxicities is a key challenge for emergency oncology services; this has become part of routine cancer care.
CitationCooksley T, Stutman R, Klotz A. Emergency management of immune-related toxicity. Curr Opin Oncol. 2020;32(4):274-81.
JournalCurrent Opinion in Oncology
- Adverse events associated with immune checkpoint inhibitor treatment for cancer.
- Authors: Esfahani K, Meti N, Miller WH Jr, Hudson M
- Issue date: 2019 Jan 14
- Atypical autoimmune adverse effects with checkpoint blockade therapies.
- Authors: Friedman CF, Snyder A
- Issue date: 2017 Feb 1
- Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
- Authors: Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR
- Issue date: 2017 Oct 1
- Emergency presentations in patients treated with immune checkpoint inhibitors.
- Authors: Cooksley T, Gupta A, Al-Sayed T, Lorigan P
- Issue date: 2020 May
- Immune-related adverse events of immune checkpoint inhibitors: a brief review.
- Authors: Myers G
- Issue date: 2018 Oct